PMID- 35079380
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240405
IS  - 2050-0904 (Print)
IS  - 2050-0904 (Electronic)
IS  - 2050-0904 (Linking)
VI  - 10
IP  - 1
DP  - 2022 Jan
TI  - Real-world evidence for subcutaneous infliximab (CT-P13 SC) treatment in patients 
      with psoriatic arthritis during the coronavirus disease (COVID-19) pandemic: A 
      case series.
PG  - e05205
LID - 10.1002/ccr3.5205 [doi]
LID - e05205
AB  - The COVID-19 pandemic highlighted the benefits of subcutaneous (SC) 
      administration for healthcare systems. The first SC infliximab, CT-P13 SC, was 
      safe and effective for the treatment of psoriatic arthritis. Observed patient 
      preferences for continuing CT-P13 SC suggest that patients receiving IV 
      infliximab should be offered a switch to CT-P13 SC.
CI  - (c) 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
FAU - Baraliakos, Xenofon
AU  - Baraliakos X
AD  - Ruhr-Universitat Bochum Rheumazentrum Ruhrgebiet Herne Germany.
FAU - Tsiami, Styliani
AU  - Tsiami S
AD  - Ruhr-Universitat Bochum Rheumazentrum Ruhrgebiet Herne Germany.
FAU - Vijayan, Sooraj
AU  - Vijayan S
AD  - Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust 
      Wolverhampton UK.
AD  - SUT Academy of Medical Sciences Thiruvananthapuram India.
FAU - Jung, Haewon
AU  - Jung H
AD  - Celltrion Healthcare Co., Ltd Incheon Korea.
FAU - Barkham, Nick
AU  - Barkham N
AUID- ORCID: 0000-0001-7754-6931
AD  - Department of Rheumatology New Cross Hospital Royal Wolverhampton NHS Trust 
      Wolverhampton UK.
LA  - eng
PT  - Case Reports
DEP - 20220120
PL  - England
TA  - Clin Case Rep
JT  - Clinical case reports
JID - 101620385
PMC - PMC8777045
OTO - NOTNLM
OT  - COVID-19
OT  - CT-P13 SC
OT  - infliximab SC
OT  - infliximab subcutaneous
OT  - psoriatic arthritis
OT  - real-world evidence
COIS- Xenofon Baraliakos has received honoraria, grants, and participated in advisory 
      boards for AbbVie, Amgen, Bristol Myers Squibb, Chugai, Galapagos, Gilead, Lilly, 
      MSD, Novartis, Pfizer, Roche, Sandoz, and UCB. Haewon Jung is an employee of 
      Celltrion Healthcare Co., Ltd. Nick Barkham has received honoraria and speakers 
      fees from Celltrion. Styliani Tsiami and Sooraj Vijayan have no potential 
      conflicts of interest to declare.
EDAT- 2022/01/27 06:00
MHDA- 2022/01/27 06:01
PMCR- 2022/01/20
CRDT- 2022/01/26 05:30
PHST- 2021/10/12 00:00 [received]
PHST- 2021/11/29 00:00 [revised]
PHST- 2021/11/30 00:00 [accepted]
PHST- 2022/01/26 05:30 [entrez]
PHST- 2022/01/27 06:00 [pubmed]
PHST- 2022/01/27 06:01 [medline]
PHST- 2022/01/20 00:00 [pmc-release]
AID - CCR35205 [pii]
AID - 10.1002/ccr3.5205 [doi]
PST - epublish
SO  - Clin Case Rep. 2022 Jan 20;10(1):e05205. doi: 10.1002/ccr3.5205. eCollection 2022 
      Jan.